DelveInsight’s “Seborrheic Dermatitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Seborrheic Dermatitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Seborrheic Dermatitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Seborrheic Dermatitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Seborrheic Dermatitis: An Overview
Seborrhoeic dermatitis is a common chronic inflammatory skin condition, characterized by scaling and poorly defined erythematous patches. It may be associated with pruritus, and it primarily affects sebum-rich areas, such as the scalp, face, upper chest, and back, A milder variant is dandruff, which is manifested by dry, flaking scales on the scalp. The extent of involvement, as well as the severity of symptoms, helps to dictate treatment.
Its clinical diagnosis is based on the location and appearance of lesions. In infants, it may present as thick white or yellow greasy scales on the scalp; it is usually benign and resolves spontaneously. In adolescents and adults, Seborrhoeic dermatitis typically presents as flaky, greasy, erythematous patches on the scalp, nasolabial folds, ears, eyebrows, anterior chest, or upper back.
Treatment with antifungal agents such as topical ketoconazole is the mainstay of therapy for Seborrhoeic dermatitis of the face and body. Because of possible adverse effects, anti-inflammatory agents such as topical corticosteroids and calcineurin inhibitors should be used only for short durations.
Several over-the-counter shampoos are available for the treatment of Seborrhoeic dermatitis of the scalp, and patients should be directed to initiate therapy with one of these agents. Antifungal shampoos (long-term) and topical corticosteroids (short-term) can be used as second-line agents for the treatment of scalp Seborrhoeic dermatitis.
Seborrhoeic dermatitis typically occurs in healthy persons. Its prevalence is 1% to 3% in the general population and 34% to 83% in immunocompromised persons. It has a bimodal distribution, with peaks at 2 to 12 months of age and in adolescence and early adulthood. It is more common in men and is typically more severe in cold and dry climates and during periods of increased stress.
Seborrheic Dermatitis Market Key Facts
-
As per Berk & Scheinfeld, (2010) the prevalence of Seborrhoeic dermatitis is limited by the absence of validated diagnostic criteria as well as a grading scale of severity; however, as one of the most common skin disorders, in the US, it affects approximately 11.6% of the general population and up to 70% of infants in the first three months of life may have the condition. Among adults, the peak incidence is in the third and fourth decades of life.
-
According to Clark et al. (2015), the prevalence of seborrheic dermatitis is 1% to 3% in the general population and 34% to 83% in immune-compromised persons. It has a bimodal distribution, with peaks at two to 12 months of age and in adolescence and early adulthood.
-
As per Berl et al., the worldwide prevalence of seborrheic dermatitis is around 5%, but the prevalence of its non-inflammatory variant, dandruff, is probably closer to 50%.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Seborrheic Dermatitis pipeline therapies. It also thoroughly assesses the Seborrheic Dermatitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Seborrheic Dermatitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Seborrheic Dermatitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Seborrheic Dermatitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Seborrheic Dermatitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Seborrheic Dermatitis Epidemiology, Segmented as –
-
Total Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]
-
Treated Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]
-
Gender-specific Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]
-
Diagnosed Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]
-
Age-specific Prevalent Pool of Seborrheic dermatitis in the 7MM [2019–2032]
Seborrheic Dermatitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Seborrheic Dermatitis market or expected to be launched during the study period. The analysis covers the Seborrheic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Seborrheic Dermatitis drugs based on their sale and market share.
The report also covers the Seborrheic Dermatitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Seborrheic Dermatitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Seborrheic Dermatitis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-market
Seborrheic Dermatitis Therapeutics Analysis
To treat this condition several alternatives are available which include calcineurin inhibitors sulfur or sulfonamide combinations, or propylene glycol. Class IV or lower corticosteroid creams, lotions, or solutions can be used for acute flares. Systemic ketoconazole or fluconazole may help if seborrheic dermatitis is severe or unresponsive. However, the use of topical steroids should be limited and appropriate for the body site to limit the risk of side effects, including epidermal and dermal atrophy, skin dyspigmentation, telangiectasia, and striae.
Pharmacologic treatment options for Seborrheic Dermatitis include antifungal preparations and anti-inflammatory agents. Antifungal preparations include selenium sulfide, pyrithione zinc, azole agents, sodium sulfacetamide, and topical terbinafine that decrease colonization by lipophilic yeast and anti-inflammatory agents including topical steroids. Creams containing antifungal and/or corticosteroid can be used for the face and trunk. Agents that help to exfoliate the such as salicylic acid are also useful.
In the pursuit of therapeutic advancements for Seborrhoeic Dermatitis, around five notable companies are actively involved in developing treatments. Among these, Arcutis Biotherapeutics is a key player, with Seborrhoeic Dermatitis drug candidates progressing to the mid to advanced stage, Phase II clinical trials.
Seborrheic Dermatitis Companies Actively Working in the Therapeutics Market Include
-
Amorepacific
-
ArcutisBiotherapeutics
-
AstionPharmaA/S
-
CutaneaLifeSciences
-
DermBiont
-
MatriSysBio
And Many Others
Emerging and Marketed Seborrheic Dermatitis Therapies Covered in the Report Include:
-
Topical roflumilast foam (ARQ-154): Arcutis Biotherapeutics
-
Omiganan (CLS002): Cutanea Life Sciences
-
DBI-002: DermBiont
-
PAC-14028: Amorepacific
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Seborrheic Dermatitis Competitive Intelligence Analysis
4. Seborrheic Dermatitis Market Overview at a Glance
5. Seborrheic Dermatitis Disease Background and Overview
6. Seborrheic Dermatitis Patient Journey
7. Seborrheic Dermatitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Seborrheic Dermatitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Seborrheic Dermatitis Unmet Needs
10. Key Endpoints of Seborrheic Dermatitis Treatment
11. Seborrheic Dermatitis Marketed Therapies
12. Seborrheic Dermatitis Emerging Drugs and Latest Therapeutic Advances
13. Seborrheic Dermatitis Seven Major Market Analysis
14. Attribute Analysis
15. Seborrheic Dermatitis Market Outlook (In US, EU5, and Japan)
16. Seborrheic Dermatitis Companies Active in the Market
17. Seborrheic Dermatitis Access and Reimbursement Overview
18. KOL Views on the Seborrheic Dermatitis Market
19. Seborrheic Dermatitis Market Drivers
20. Seborrheic Dermatitis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/seborrhoeic-dermatitis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Generalized Pustular Psoriasis Market
“Generalized Pustular Psoriasis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Generalized Pustular Psoriasis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Generalized Pustular Psoriasis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research